Brokers Offer Predictions for Envoy Medical Q1 Earnings

Envoy Medical, Inc. (NASDAQ:COCH) – HC Wainwright issued their Q1 2027 earnings estimates for shares of Envoy Medical in a research report issued on Wednesday, July 15th. HC Wainwright analyst Y. Chen expects that the company will post earnings per share of ($0.06) for the quarter. HC Wainwright currently has a “Buy” rating and a $2.50 price target on the stock. The consensus estimate for Envoy Medical’s current full-year earnings is ($0.30) per share. HC Wainwright also issued estimates for Envoy Medical’s Q2 2027 earnings at ($0.06) EPS, Q3 2027 earnings at ($0.05) EPS, Q4 2027 earnings at ($0.03) EPS and FY2027 earnings at ($0.19) EPS.

A number of other analysts have also recently commented on the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Envoy Medical in a research report on Friday, April 24th. Zacks Research upgraded Envoy Medical to a “hold” rating in a research note on Wednesday, April 1st. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Envoy Medical currently has a consensus rating of “Hold” and a consensus price target of $2.50.

Envoy Medical Stock Performance

Shares of NASDAQ COCH opened at $0.76 on Thursday. Envoy Medical has a fifty-two week low of $0.36 and a fifty-two week high of $1.89. The company has a 50 day simple moving average of $0.69 and a two-hundred day simple moving average of $0.68. The company has a market capitalization of $58.44 million, a price-to-earnings ratio of -0.75 and a beta of 1.88.

Envoy Medical (NASDAQ:COCH) last posted its quarterly earnings data on Monday, May 11th. The company reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.03. The business had revenue of $0.04 million for the quarter, compared to the consensus estimate of $0.10 million.

Hedge Funds Weigh In On Envoy Medical

Hedge funds have recently added to or reduced their stakes in the company. DSG Capital Advisors LLC bought a new position in Envoy Medical in the 1st quarter valued at approximately $416,000. Focus Partners Wealth bought a new stake in shares of Envoy Medical in the 1st quarter worth $276,000. Geode Capital Management LLC increased its holdings in shares of Envoy Medical by 111.3% in the 4th quarter. Geode Capital Management LLC now owns 98,351 shares of the company’s stock worth $65,000 after purchasing an additional 51,813 shares in the last quarter. Finally, CIBC Bancorp USA Inc. purchased a new position in shares of Envoy Medical in the third quarter worth $60,000. 8.59% of the stock is currently owned by hedge funds and other institutional investors.

More Envoy Medical News

Here are the key news stories impacting Envoy Medical this week:

• Positive Sentiment: HC Wainwright reiterated a Buy rating on Envoy Medical and kept its $2.50 price target, signaling strong upside potential. Benzinga article
• Positive Sentiment: The analyst published new FY2027 and quarterly EPS estimates, forecasting losses that are smaller over time, which suggests improving profitability trends and can support investor sentiment.
• Neutral Sentiment: HC Wainwright’s FY2027 EPS estimate of $(0.19) was better than the current consensus estimate of $(0.30), but the company is still expected to remain unprofitable in the near term.
• Neutral Sentiment: Additional report summaries outlined Q1 2027 EPS of $(0.06), Q2 2027 EPS of $(0.06), Q3 2027 EPS of $(0.05), and Q4 2027 EPS of $(0.03), reinforcing a gradual improvement profile rather than a near-term earnings swing.

About Envoy Medical

Envoy Medical (NASDAQ:COCH) is a medical device company focused on non-invasive neuromodulation therapies for dysphagia, a swallowing disorder that affects patients following neurological events or due to degenerative conditions. The company’s lead technology delivers targeted electrical stimulation designed to strengthen the muscles and neural pathways involved in the swallowing process.

Envoy Medical’s flagship therapy has received regulatory clearance from the U.S. Food and Drug Administration and is being introduced through rehabilitation centers, speech-language pathology clinics and acute care hospitals.